'Designer' pill set to cut melanoma deaths by almost two-thirds

A new era in the treatment of skin cancer was heralded by doctors yesterday as they unveiled what has been called the biggest breakthrough in 30 years.

A twice-a-day pill that targets a faulty gene present in melanoma, the deadliest form of skin cancer, has been shown to reduce the risk of death by almost two-thirds in patients with the advanced form of the disease.

James Larkin of the Royal Marsden Hospital in London, the principal investigator in the UK, said: "This is a pivotal moment. Without question, the results of this trial represent a turning point in the treatment of this disease."

Professor Richard Marais of the Institute of Cancer Research, who first demonstrated the importance of the gene in melanoma, said: "This is the biggest breakthrough in melanoma treatment in more than 30 years. The results demonstrate for the first time that a targeted therapy can work and will change our approach to treating this disease. It is an enormous advance in the field."

The drug is the first "personalised" treatment for melanoma, designed to target cases of the disease which carry the faulty gene, called a BRAF mutation, which account for about half of all cases. As such, it marks a milestone in the transformation of cancer medicines from blunderbuss treatments for everybody to designer drugs tailored to individual cases.

Melanoma has been the fastest rising cancer in the UK over the past 25 years, with more than 10,000 cases a year and 2,000 deaths. It is the second most common cancer in young adults aged 15 to 34 and affects twice as many women as men, although more men die of it.

A typical victim is the pale-skinned office worker who spends two weeks broiling on a Mediterranean beach until their skin is red and blistered. Covering up in the midday sun and using high-factor sun cream is the best defence against the cancer.

The international drug trial involved 670 patients in the US, Canada, Europe and Australia, including 50 in the UK. It showed survival rates at six months increased from 64 per cent for those on standard chemotherapy to 84 per cent on the new drug, called vemurafenib.

The improvement was so dramatic that three months into the trial participants receiving standard chemotherapy were offered the chance to switch to vemurafenib.

The findings were published yesterday by the New England Journal of Medicine and were presented at the annual meeting of the American Society for Clinical Oncology in Chicago.

Dr Larkin said: "For the last few decades we have treated melanoma with chemotherapy and it didn't work very well. Now that we understand the biology of the disease we can target the genes responsible. We know the BRAF mutation drives the disease."

Roche, the Swiss multinational, developed the drug with its partner Plexxikon, a biotech company which is also developing a test to screen patients for the BRAF mutation.

The companies are likely to apply for a licence for vemurafenib later this year. It is expected to cost tens of thousands of pounds per patient per year.

PROMOTED VIDEO
Life and Style
ebookNow available in paperback
ebooks
ebookPart of The Independent’s new eBook series The Great Composers
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Tradewind Recruitment: French & German Teacher

    £120 - £145 per day: Tradewind Recruitment: French & German Teacher X2 Materni...

    Recruitment Genius: IT Support Engineer / Systems Administrator

    £25000 - £32500 per annum: Recruitment Genius: Based in SW London, this compan...

    Recruitment Genius: Project Coordinator

    Negotiable: Recruitment Genius: Due to expansion this leading designer and sup...

    Recruitment Genius: Recruitment Assistant

    £19000 - £21000 per annum: Recruitment Genius: Are you a friendly, confident i...

    Day In a Page

    Isis hostage crisis: The prisoner swap has only one purpose for the militants - recognition its Islamic State exists and that foreign nations acknowledge its power

    Isis hostage crisis

    The prisoner swap has only one purpose for the militants - recognition its Islamic State exists and that foreign nations acknowledge its power, says Robert Fisk
    Missing salvage expert who found $50m of sunken treasure before disappearing, tracked down at last

    The runaway buccaneers and the ship full of gold

    Salvage expert Tommy Thompson found sunken treasure worth millions. Then he vanished... until now
    Homeless Veterans appeal: ‘If you’re hard on the world you are hard on yourself’

    Homeless Veterans appeal: ‘If you’re hard on the world you are hard on yourself’

    Maverick artist Grayson Perry backs our campaign
    Assisted Dying Bill: I want to be able to decide about my own death - I want to have control of my life

    Assisted Dying Bill: 'I want control of my life'

    This week the Assisted Dying Bill is debated in the Lords. Virginia Ironside, who has already made plans for her own self-deliverance, argues that it's time we allowed people a humane, compassionate death
    Move over, kale - cabbage is the new rising star

    Cabbage is king again

    Sophie Morris banishes thoughts of soggy school dinners and turns over a new leaf
    11 best winter skin treats

    Give your moisturiser a helping hand: 11 best winter skin treats

    Get an extra boost of nourishment from one of these hard-working products
    Paul Scholes column: The more Jose Mourinho attempts to influence match officials, the more they are likely to ignore him

    Paul Scholes column

    The more Jose Mourinho attempts to influence match officials, the more they are likely to ignore him
    Frank Warren column: No cigar, but pots of money: here come the Cubans

    Frank Warren's Ringside

    No cigar, but pots of money: here come the Cubans
    Isis hostage crisis: Militant group stands strong as its numerous enemies fail to find a common plan to defeat it

    Isis stands strong as its numerous enemies fail to find a common plan to defeat it

    The jihadis are being squeezed militarily and economically, but there is no sign of an implosion, says Patrick Cockburn
    Virtual reality thrusts viewers into the frontline of global events - and puts film-goers at the heart of the action

    Virtual reality: Seeing is believing

    Virtual reality thrusts viewers into the frontline of global events - and puts film-goers at the heart of the action
    Homeless Veterans appeal: MP says Coalition ‘not doing enough’

    Homeless Veterans appeal

    MP says Coalition ‘not doing enough’ to help
    Larry David, Steve Coogan and other comedians share stories of depression in new documentary

    Comedians share stories of depression

    The director of the new documentary, Kevin Pollak, tells Jessica Barrett how he got them to talk
    Has The Archers lost the plot with it's spicy storylines?

    Has The Archers lost the plot?

    A growing number of listeners are voicing their discontent over the rural soap's spicy storylines; so loudly that even the BBC's director-general seems worried, says Simon Kelner
    English Heritage adds 14 post-war office buildings to its protected lists

    14 office buildings added to protected lists

    Christopher Beanland explores the underrated appeal of these palaces of pen-pushing
    Human skull discovery in Israel proves humans lived side-by-side with Neanderthals

    Human skull discovery in Israel proves humans lived side-by-side with Neanderthals

    Scientists unearthed the cranial fragments from Manot Cave in West Galilee